|

Ribociclib 600mg Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: Kisqali

Pipeline

Phase 1: 1Phase 3: 1

Top Sponsors

  • Relay Therapeutics, Inc.1
  • American Society of Clinical Oncology1

Indications

  • Metastatic Breast Cancer2
  • Breast Cancer2
  • Cancer2
  • PIK3CA Mutation1
  • Unresectable Solid Tumor1

Chandler, Arizona1 trial

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Ironwood Cancer & Research Centers

Phase 3

Tucson, Arizona1 trial

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

The University of Arizona Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.